<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2729">
  <stage>Registered</stage>
  <submitdate>8/04/2010</submitdate>
  <approvaldate>8/04/2010</approvaldate>
  <nctid>NCT01102712</nctid>
  <trial_identification>
    <studytitle>Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction</studytitle>
    <scientifictitle>Evaluation Study of Unilateral Bronchoscopic Thermal Vapor Ablation (BTVA) in Patients With Heterogeneous Emphysema and Upper Lobe Predominance</scientifictitle>
    <utrn />
    <trialacronym>BTVA</trialacronym>
    <secondaryid>Vapor-OUS</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Emphysema</healthcondition>
    <healthcondition>Chronic Obstructive Pulmonary Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - BTVA System

Experimental: BTVA - 


Treatment: devices: BTVA System
Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>increase in FEV1 = 12% or a decrease in total St. George's Respiratory Questionnaire (SGRQ) score = 4 points</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Lobar volume reduction as determined by computed tomography (CT) analysis</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in pulmonary function therapy</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement in 6 minute walk distance</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Age: &gt; 40 and = 75 years old

          2. Diagnosis of heterogeneous emphysema with upper lobe predominance

          3. FEV1 &lt; 45% predicted

          4. TLC &gt; 100% predicted

          5. RV &gt; 150% predicted

          6. 6-minute walk test &gt; 140 meters

          7. mMRC = 2 (mMRC)

          8. Non-smoking for 3 months

          9. Optimized medical management and completed pulmonary rehabilitation</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Known a-1-antitrypsin deficiency

          2. BMI &lt; 15 kg/m2 or &gt; 35 kg / m2

          3. History of pneumothorax within previous 18 months

          4. History of heart and / or lung transplant, lung volume reduction surgery (LVRS),
             median sternotomy, bullectomy, and/or lobectomy

          5. Respiratory infections or recurring COPD exacerbations &gt; 3 hospitalizations in past 12
             months or active infection

          6. History of the (EF) = 40%; Stroke; Unstable Myocardial Ischemia; FEV1 &lt; 15% predicted;
             DLCO &lt; 20% predicted; pulmonary hypertension; indwelling pacemaker or implantable
             cardiac defibrillator (ICD); pregnancy or breastfeeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>34</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>Prince Charles Hospital - Chermside</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <postcode>4032 - Chermside</postcode>
    <postcode>3181 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Klagenfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Berka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heildelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hemer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nurnberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Uptake Medical Corp</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To establish and confirm the safety and clinical utility of BTVA applied unilaterally for
      lung volume reduction in patients with upper lobe predominate heterogeneous severe emphysema.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01102712</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>